Literature DB >> 15551296

The relationship of postprandial glucose to HbA1c.

Rüdiger Landgraf1.   

Abstract

The gold standard for the assessment of the overall glycemic control is the determination of HbA1c. There are, however, insufficient data to determine reliably the relative contribution of fasting and postprandial plasma glucose to HbA1c. Increasing evidence suggests that excessive excursions of postprandial glucose might be important for the development of micro- and macroangiopathic complications. With respect to the treatment options, one important question to be answered is whether premeal, postmeal or fasting plasma glucose, alone or in combination, will be necessary in adjusting the therapy to achieve optimal HbA1c levels while minimizing hypoglycemia. HbA1c is difficult to predict from fasting plasma glucose. There are indications that there is a shift in the relative contribution from postprandial glucose at good to fair HbA1c levels (<7.3% to <9.2%) to fasting plasma glucose at high HbA1c (>9.3%). There is also a better correlation of afternoon and evening plasma glucose with HbA1c than with prebreakfast and prelunch plasma glucose values. Since the definition on how to define postprandial glucose is still a matter of debate and since postprandial glucose depends on the premeal blood glucose level and, on the time of the meal, its size and composition and the therapeutic strategy, the data so far available are inconclusive and the best correlation of HbA1c is with the area under the glucose profiles. Continuous glucose monitoring under daily life conditions will be the key to definitely unravel the relationship among HbA1c and fasting, premeal, postprandial and postabsorptive plasma glucose. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15551296     DOI: 10.1002/dmrr.517

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  11 in total

1.  Glucose information for tight glycemic control: different methods with different challenges.

Authors:  Christian Weber; Kurt Neeser
Journal:  J Diabetes Sci Technol       Date:  2010-09-01

2.  Hemoglobin A1c and Self-Monitored Average Glucose: Validation of the Dynamical Tracking eA1c Algorithm in Type 1 Diabetes.

Authors:  Boris P Kovatchev; Marc D Breton
Journal:  J Diabetes Sci Technol       Date:  2015-11-09

3.  How should HbA1c measurements be reported?

Authors:  F Gorus; C Mathieu; E Gerlo
Journal:  Diabetologia       Date:  2006-01       Impact factor: 10.122

4.  The relative contribution of diurnal and nocturnal glucose exposures to HbA1c in type 1 diabetes males: a pooled analysis.

Authors:  Matthew D Campbell; Daniel J West; Lauren L O'Mahoney; Sam Pearson; Noppadol Kietsiriroje; Mel Holmes; Ramzi A Ajjan
Journal:  J Diabetes Metab Disord       Date:  2022-03-31

5.  Altered disease course after initiation of self-monitoring of blood glucose in noninsulin-treated type 2 diabetes (ROSSO 3).

Authors:  Hubert Kolb; Berthold Schneider; Lutz Heinemann; Volker Lodwig; Werner A Scherbaum; Stephan Martin
Journal:  J Diabetes Sci Technol       Date:  2007-07

6.  Accuracy and robustness of dynamical tracking of average glycemia (A1c) to provide real-time estimation of hemoglobin A1c using routine self-monitored blood glucose data.

Authors:  Boris P Kovatchev; Frank Flacke; Jochen Sieber; Marc D Breton
Journal:  Diabetes Technol Ther       Date:  2013-12-03       Impact factor: 6.118

7.  Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes.

Authors:  Timothy Colin Hardman; Simon William Dubrey
Journal:  Diabetes Ther       Date:  2011-06-28       Impact factor: 2.945

8.  Interpretation of metabolic memory phenomenon using a physiological systems model: What drives oxidative stress following glucose normalization?

Authors:  Veronika Voronova; Kirill Zhudenkov; Gabriel Helmlinger; Kirill Peskov
Journal:  PLoS One       Date:  2017-02-08       Impact factor: 3.240

Review 9.  Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes.

Authors:  Nazia Raja-Khan; Sarah S Warehime; Robert A Gabbay
Journal:  Vasc Health Risk Manag       Date:  2007

Review 10.  Lixisenatide as add-on therapy to basal insulin.

Authors:  Dominique Xavier Brown; Emma Louise Butler; Marc Evans
Journal:  Drug Des Devel Ther       Date:  2013-12-13       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.